Platelet soluble CD40L and matrix metalloproteinase 9 activity are proinflammatory mediators in Behçet disease patients

Summary

Platelets are the major source of plasma-soluble CD40L (sCD40L), an important inflammatory mediator. This study explored the impact of platelet-derived sCD40L on Behçet disease (BD), an autoinflammatory vasculitis. We also searched for influences by platelet matrix metalloproteinases (MMP) –2 and MMP-9, implicated in several inflammatory diseases, on CD40L shedding from platelet membrane. Platelet activation were studied by flow cytometry and aggregometry, surface expression of CD40L and platelet-leukocyte aggregates by flow cytometry, sCD40L by ELISA, cellular CD40L and CD40 levels by Western blot and MMPs activity by gelatin zymography. The effect of sCD40L on MMP9 expression was studied in cultured MEG-01 cells. Plasma and platelet-released sCD40L levels were higher in BD patients. No differences in platelet activation and in platelet-leukocyte aggregates formation were observed between BD patients and controls. Plasma and platelet MMP-9 levels were increased in BD patients, whereas there was no difference in platelet MMP-2 activity. Since a correlation between plasma sCD40L and platelet MMP-9 activity was observed, we studied the influence of sCD40L on MMP-9 levels in the megakaryoblastic cell line MEG-01. Treatment of MEG-01 cells with recombinant sCD40L increased MMP-9 but did not change MMP-2 levels. In conclusion, sCD40L release from platelets was mediated by MMP-9, and MMP-9 expression was in turn upregulated by sCD40L in the MEG-01 cell line. We conclude that platelets and megakaryocytes might participate in a positive feedback loop occurring between sCD40L and MMP-9 which would contribute to the proinflammatory state observed in BD.

Keywords

Behçet disease - CD40L - matrix metalloproteinase 9 - platelets - MEG-01 cells

^* These authors contributed equally to this work.

• References

• 1 Sakane T, Takeno M, Suzuki N. et al. Behçet’s disease. N Engl J Med 1999; 341: 1284-1291.
• 2 Mege JL, Dilsen N, Sanguedolce V. et al. Overproduction of monocyte derived tumor necrosis factor alpha, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Behcet’s disease. A comparative study with familial Mediterranean fever and healthy subjects. J Rheumatol 1993; 20: 1544-1549.
• 3 Direskeneli H. Behcet’s disease: infectious aetiology, new autoantigens, and HLA-B51. Ann Rheum Dis 2001; 60: 996-1002.
• 4 Direskeneli H. Autoimmunity vs autoinflammation in Behcet’s disease: do we oversimplify a complex disorder?. Rheumatology 2006; 45: 1461-1465.
• 5 Aukrust P, Waehre T, Damås JK. et al. Inflammatory role of platelets in acute coronary syndromes. Heart 2001; 86: 605-606.
• 6 Anand SX, Viles-Gonzalez JF, Badimón JJ. et al. Membrane-associated CD40L and sCD40L in atherotrombotic disease. Thromb Haemost 2003; 90: 377-384.
• 7 Menchén L, Marín-Jiménez I, Arias-Salgado EG. et al. Matrix metalloproteinase 9 is involved in Crohn's disease-associated platelet hyperactivation through the release of soluble CD40 ligand. Gut 2009; 58: 920-928.
• 8 Choi WS, Jeon OH, Kim DS. CD40 ligand shedding is regulated by interaction between matrix metalloproteinase-2 and platelet integrin alpha(IIb)beta(3). J Thromb Haemost 2010; 08: 1364-1371.
• 9 Lievens D, Eijgelaar WJ, Biessen EA. et al. The multi-functionality of CD40L and its receptor CD40 in atherosclerosis. Thromb Haemost 2009; 102: 206-214.
• 10 Lievens D, Zernecke A, Seijkens T. et al. Platelet CD40L mediates thrombotic and inflammatory processes in atherosclerosis. Blood 2010; 116: 4317-4327.
• 11 Missiou A, Wolf D, Platzer I. et al. CD40L induces inflammation and adipogenesis in adipose cells--a potential link between metabolic and cardiovascular disease. Thromb Haemost 2010; 103: 788-796.
• 12 Poggi M, Engel D, Christ A. et al. CD40L Deficiency Ameliorates Adipose Tissue Inflammation and Metabolic Manifestations of Obesity in Mice. Arterioscler Thromb Vasc Biol 2011; 31: 2251-2260.
• 13 Andre P, Nannizzi-Alaimo L, Prasad SK. et al. Platelet-derived CD40L: the switch-hitting player of cardiovascular disease. Circulation 2002; 106: 896-899.
• 14 Aukrust P, Müller F, Ueland T. et al. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation 1999; 100: 614-620.
• 15 Garlichs CD, Eskafi S, Raaz D. et al. Patients with acute coronary syndromes express enhanced CD40 ligand/CD154 on platelets. Heart 2001; 86: 649-655.
• 16 Nannizzi-Alaimo L, Rubenstein MH, Alves VL. et al. Cardiopulmonary bypass induces release of soluble CD40 ligand. Circulation 2002; 105: 2849-2854.
• 17 Kato K, Santana-Sahagún E, Rassenti LZ. et al. The soluble CD40 ligand sCD154 in systemic lupus erythematosus. J Clin Invest 1999; 104: 947-955.
• 18 Danese S, de la Motte C, Fiocchi C. Platelets in inflammatory bowel disease: clinical, pathogenic, and therapeutic implications. Am J Gastroenterol 2004; 99: 938-945.
• 19 International Study Group for Behçet’s disease. Criteria for diagnosis of Behçet’s disease. Lancet 1990; 335: 1078-1080.
• 20 Bhakta BB, Brennan P, James TE. et al. Behçet’s disease: evaluation of a new instrument to measure clinical activity. Rheumatology 1999; 38: 728-733.
• 21 Ogura M, Morishima Y, Ohno R. et al. Establishment of a novel human mega-karyoblastic leukemia cell line, MEG-01, with positive Philadelphia chromosome. Blood 1985; 66: 1384-1392.
• 22 André P, Prasad KS, Denis CV. et al. CD40L stabilizes arterial thrombi by a beta3 integrin--dependent mechanism. Nat Med 2002; 08: 247-252.
• 23 Furman MI, Krueger LA, Linden MD. et al. Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization. J Am Coll Cardiol 2004; 43: 2319-2325.
• 24 Koç Y, Güllü I, Akpek G. et al. Vascular involvement in BD Behçet’s disease. J Rheumatol 1992; 19: 402-410.
• 25 Calamia KT, Schirmer M, Melikoglu M. Major vessel involvement in Behçet’s disease. Curr Opin Rheumatol 2005; 17: 1-8.
• 26 Pay S, Abbasov T, Erdem H. et al. Serum MMP-2 and MMP-9 in patients with Behçet’s disease: do their higher levels correlate to vasculo-Behçet’s disease associated with aneurysm formation?. clin exp rheumatol 2007; 25: s70-75.
• 27 Descamps FJ, Kangave D, Cauwe B. et al. Interphotoreceptor retinoid-binding protein as biomarker in systemic autoimmunity with eye inflictions. J Cell Mol Med 2008; 12: 2449-2456.
• 28 Mason PJ, Chakrabarti S, Albers AA. et al. Plasma, serum, and platelet expression of CD40 ligand in adults with cardiovascular disease. Am J Cardiol 2005; 96: 1365-1369.
• 29 Viallard JF, Solanilla A, Gauthier B. et al. Increased soluble and platelet-associated CD40 ligand in essential thrombocythemia and reactive thrombocytosis. Blood 2002; 99: 2612-2614.
• 30 Jung K, Mannello F, Lein M. Translating molecular medicine into clinical tools: doomed to fail by neglecting basic preanalytical principles. J Transl Med 2009; 07: 87.
• 31 Gerlach RF, Demacq C, Jung K. et al. Rapid separation of serum does not avoid artificially higher matrix metalloproteinase (MMP)-9 levels in serum versus plasma. Clin Biochem 2007; 40: 119-123.
• 32 Ricart JM, Ramón LA, Vayá A. et al. Fibrinolytic inhibitor levels and polymorphisms in Behçet disease and their association with thrombosis. Br J Haematol 2008; 141: 716-719.
• 33 Yurdakul S, Hekim N, Soysal T. et al. Fibrinolytic activity and D-dimer levels in Behçet's syndrome. Clin Exp Rheumatol 2005; 23: S53-58.
• 34 Akar S, Ozcan MA, Ates H. et al. Circulated activated platelets and increased platelet reactivity in patients with Behçet's disease. Clin Appl Thromb Hemost 2006; 12: 451-457.
• 35 Martínez M, Ricart JM, Ruiz-Aja S. et al Platelet activation and red blood cell phosphatidylserine exposure evaluated by flow cytometry in patients with Behçet's disease: are they related to thrombotic events?. Pathophysiol Haemost Thromb 2007; 36: 18-22.
• 36 Varo N, Libby P, Nuzzo R. et al. Elevated release of sCD40L from platelets of diabetic patients by thrombin, glucose and advanced glycation end products. Diab Vasc Dis Res 2005; 02: 81-87.
• 37 Tousoulis D, Zisimos K, Antoniades C. et al. Oxidative stress and inflammatory process in patients with atrial fibrillation: The role of left atrium distension. Int J Cardiol 2009; 136: 258-262.
• 38 Ohashi Y, Kawashima S, Mori T. Soluble CD40 ligand and interleukin-6 in the coronary circulation after acute myocardial infarction. Int J Cardiol 2006; 112: 52-58.
• 39 Henn V, Steinbach S, Buchner K. et al. The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40. Blood 2001; 98: 1047-1054.
• 40 Chen C, Chai H, Wang X. Soluble CD40 ligand induces endothelial dysfunction in human and porcine coronary artery endothelial cells. Blood 2008; 112: 3205-3216.
• 41 Freysdottir J, Lau S, Fortune F. Gammadelta T cells in Behçet’s disease (BD) and recurrent aphthous stomatitis (RAS). Clin Exp Immunol 1999; 118: 451-457.
• 42 Hamzaoui K, Hamzaoui A, Guemira F. et al. Cytokine profile in Behçet’s disease patients. Relationship with disease activity. Scand J Rheumatol 2002; 31: 205-210.
• 43 Law CL, Grewal IS. Therapeutic interventions targeting CD40L (CD154) and CD40: The Opportunities and Challenges. Adv Exp Med Biol 2009; 647: 8-36.
• 44 Boumpas DT, Furie R, Manzi S. et al. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum 2003; 48: 719-727.
• 45 Schönbeck U, Mach F, Sukhova GK. et al. Regulation of matrix metalloproteinase expression in human vascular smooth muscle cells by T lymphocytes: a role for CD40 signaling in plaque rupture?. Circ Res 1997; 81: 448-454.
• 46 Li G, Sanders JM, Bevard MH. et al. CD40 ligand promotes Mac-1 expression, leukocyte recruitment, and neointima formation after vascular injury. Am J Pathol 2008; 172: 1141-1152.
• 47 Smola-Hess S, Schnitzler R, Hadaschik D. et al. CD40L induces matrix-metalloproteinase-9 but not tissue inhibitor of metalloproteinases-1 in cervical carcinoma cells: imbalance between NF-kappaB and STAT3 activation. Exp Cell Res 2001; 267: 205-215.
• 48 Lollini PL, Landuzzi L, Frabetti F. et al. Expression of functional CD40 on human osteosarcoma and Ewing's sarcoma cells. Clin Cancer Res 1998; 04: 1843-1849.
• 49 Mach F, Schönbeck U, Fabunmi RP. et al. T lymphocytes induce endothelial cell matrix metalloproteinase expression by a CD40L-dependent mechanism: implications for tubule formation. Am J Pathol 1999; 154: 229-238.
• 50 Baharav E, Weinberger A, Mor F. Experimental models of Behçet’s Disease. Drug Disc Today: Dis Models 2006; 03: 11-14.
• 51 Hermann A, Rauch BH, Braun M. et al. Platelet CD40 ligand (CD40L)-subcellular localization, regulation of expression, and inhibition by clopidogrel. Platelets 2001; 12: 74-82.
• 52 Cecchetti L, Tolley ND, Michetti N. et al. Megakaryocytes differentially sort mRNAs for matrix metalloproteinases and their inhibitors into platelets: a mechanism for regulating synthetic events. Blood 2011; 118: 1903-1911.
• 53 Zhou L, Ismaili J, Stordeur P. et al. Inhibition of the CD40 pathway of monocyte activation by triazolopyrimidine. Clin Immunol 1999; 93: 232-238.
• 54 Zhou L, Schandené L, Mordvinov VA. et al. Trapidil inhibits monocyte CD40 expression by preventing IFN-gamma-induced STAT1 S727 phosphorylation. Int Immunopharmacol 2004; 04: 863-871.
• 55 Kato Y, Tsuda T, Hosaka Y. et al. Effects of trapidil on effector functions of monocytes related to atherosclerotic plaque. Eur J Pharmacol 2001; 428: 371-379.
• 56 Lutgens E, Lievens D, Beckers L. et al. Deficient CD40-TRAF6 signaling in leukocytes prevents atherosclerosis by skewing the immune response toward an antiinflammatory profile. J Exp Med 2010; 207: 391-404.